167 related articles for article (PubMed ID: 28691327)
21. Human papillomavirus vaccines: current status and future prospects.
Garland SM; Smith JS
Drugs; 2010 Jun; 70(9):1079-98. PubMed ID: 20518577
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
[TBL] [Abstract][Full Text] [Related]
23. Worldwide impact of the human papillomavirus vaccine.
Hakim AA; Dinh TA
Curr Treat Options Oncol; 2009 Apr; 10(1-2):44-53. PubMed ID: 19387841
[TBL] [Abstract][Full Text] [Related]
24. Betwixt and Between Well and Sick in Cervical Precancer: Canadian Women's Experiences of Recurring HPV Infections and HPV Vaccination.
Wyndham-West M; Durand N; Santoro A
Can J Nurs Res; 2018 Sep; 50(3):120-132. PubMed ID: 29759001
[TBL] [Abstract][Full Text] [Related]
25. [Prevention of cervical cancer (II): prophylactic HPV vaccination, current knowledge, practical procedures and new issues].
Monsonego J
Presse Med; 2007 Apr; 36(4 Pt 2):640-66. PubMed ID: 17350792
[TBL] [Abstract][Full Text] [Related]
26. Global elimination of cervical cancer is achievable-with commitment.
The Lancet Oncology
Lancet Oncol; 2019 Nov; 20(11):1467. PubMed ID: 31674306
[No Abstract] [Full Text] [Related]
27. Global Delivery of Human Papillomavirus Vaccines.
Wigle J; Fontenot HB; Zimet GD
Pediatr Clin North Am; 2016 Feb; 63(1):81-95. PubMed ID: 26613690
[TBL] [Abstract][Full Text] [Related]
28. Elimination of cervical cancer in Tanzania: Modelled analysis of elimination in the context of endemic HIV infection and active HIV control.
Hall MT; Smith MA; Simms KT; Barnabas R; Murray JM; Canfell K
Int J Cancer; 2021 Jul; 149(2):297-306. PubMed ID: 33634857
[TBL] [Abstract][Full Text] [Related]
29. Progress toward implementation of human papillomavirus vaccination--the Americas, 2006-2010.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Oct; 60(40):1382-4. PubMed ID: 21993342
[TBL] [Abstract][Full Text] [Related]
30. Human papillomavirus vaccine disease impact beyond expectations.
de Sanjose S; Brotons M; LaMontagne DS; Bruni L
Curr Opin Virol; 2019 Dec; 39():16-22. PubMed ID: 31382121
[TBL] [Abstract][Full Text] [Related]
31. Compulsory HPV vaccination.
Basu S
N Engl J Med; 2007 Mar; 356(10):1074; author reply 1074-5. PubMed ID: 17347466
[No Abstract] [Full Text] [Related]
32. Knowledge and acceptability of human papillomavirus vaccination and cervical cancer screening among women in Karnataka, India.
Montgomery MP; Dune T; Shetty PK; Shetty AK
J Cancer Educ; 2015 Mar; 30(1):130-7. PubMed ID: 25355525
[TBL] [Abstract][Full Text] [Related]
33. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe.
Poljak M; Seme K; Maver PJ; Kocjan BJ; Cuschieri KS; Rogovskaya SI; Arbyn M; Syrjänen S
Vaccine; 2013 Dec; 31 Suppl 7():H59-70. PubMed ID: 24332298
[TBL] [Abstract][Full Text] [Related]
34. [Vaccination strategies against HPV. Recommendations from a European perspective].
Deleré Y
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2009 Nov; 52(11):1065-8. PubMed ID: 19760369
[TBL] [Abstract][Full Text] [Related]
35. Prevention of human papillomavirus (HPV) infection and cervical cancer in China: how does HPV vaccination bring about benefits to Chinese women?
Liu X; Feng A; Cui Y; Tobe RG
Biosci Trends; 2013 Aug; 7(4):159-67. PubMed ID: 24056165
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive control of human papillomavirus infections and related diseases.
Bosch FX; Broker TR; Forman D; Moscicki AB; Gillison ML; Doorbar J; Stern PL; Stanley M; Arbyn M; Poljak M; Cuzick J; Castle PE; Schiller JT; Markowitz LE; Fisher WA; Canfell K; Denny LA; Franco EL; Steben M; Kane MA; Schiffman M; Meijer CJ; Sankaranarayanan R; Castellsagué X; Kim JJ; Brotons M; Alemany L; Albero G; Diaz M; de Sanjosé S;
Vaccine; 2013 Dec; 31 Suppl 5():F1-31. PubMed ID: 24331745
[TBL] [Abstract][Full Text] [Related]
37. Modeling cervical cancer prevention in developed countries.
Kim JJ; Brisson M; Edmunds WJ; Goldie SJ
Vaccine; 2008 Aug; 26 Suppl 10(Suppl 10):K76-86. PubMed ID: 18847560
[TBL] [Abstract][Full Text] [Related]
38. National implementation of HPV vaccination programs in low-resource countries: Lessons, challenges, and future prospects.
Tsu VD; LaMontagne DS; Atuhebwe P; Bloem PN; Ndiaye C
Prev Med; 2021 Mar; 144():106335. PubMed ID: 33678232
[TBL] [Abstract][Full Text] [Related]
39. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia.
Regan DG; Philp DJ; Hocking JS; Law MG
Sex Health; 2007 Sep; 4(3):147-63. PubMed ID: 17931528
[TBL] [Abstract][Full Text] [Related]
40. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
